Op-ed

Is there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation?

Authors
  • L. Van Acker
  • H. de Rooster
  • G. Serrano
  • D. Paepe
  • W. De Spiegelaere
  • N. Devriendt

Abstract

Experimental rat models and clinical trials in human patients with liver cirrhosis show evidence that supplementation with hepatotropic factors provides therapeutic benefits. This form of support has not yet been described in dogs with multiple acquired portosystemic shunts (MAPSS) despite similarities between both pathological conditions. Especially hepatocyte growth factor (HGF) and branched chain amino acids (BCAA) deserve closer attention. High-quality vegetable rather than animal proteins have been suggested to form an excellent dietary source of BCAA, and leucine seems the best candidate for supplementation given its stimulating effects on liver function in general and on HGF secretion specifically. Research on optimal ways of administration of HGF in dogs with MAPSS secondary to congenital portosystemic shunt attenuation is necessary before clinical trials can be initiated.

How to Cite:

Van Acker, L. & de Rooster, H. & Serrano, G. & Paepe, D. & De Spiegelaere, W. & Devriendt, N., (2021) β€œIs there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation?”, Vlaams Diergeneeskundig Tijdschrift 90(4), 209-215. doi: https://doi.org/10.21825/vdt.v90i4.20717

Downloads:
Download PDF
View PDF

391 Views

95 Downloads

Published on
30 Aug 2021
Peer Reviewed